Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lamivudine

FDA-approved product (tablet, oral), marketed as Epivir, Epivir-Hbv, Lamivudine.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Lamivudine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis
  • Hepatitis B virus infection
  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease
  • Infection
  • Inflammation
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF05; FDA class Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Lamivudine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA20.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli9.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lamivudine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lamivudine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)

    NCT02346487 · start 2015-09

    Registered record
    Registry ID
    NCT02346487
    Conditions
    HIV
    Interventions
    LPV/RTV pellets and AZT/3TC or ABC/3TC
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09
    Completion
    2019-05-14
    Enrolment
    1,003

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionLPV/RTV pellets and AZT/3TC or ABC/3TC
    PhasePhase 3
    Registry statusCompleted

  • HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

    NCT02513147 · start 2015-06

    Registered record
    Registry ID
    NCT02513147
    Conditions
    HIV-1
    Interventions
    Dolutegravir; PI; 2 NRTI; 2 NRTI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-11
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionDolutegravir; PI; 2 NRTI; 2 NRTI
    PhasePhase 4
    Registry statusCompleted

  • Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART

    NCT02249962 · start 2015-05

    Registered record
    Registry ID
    NCT02249962
    Conditions
    HIV; Infant Exposure to Efavirenz
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-05
    Completion
    2020-09
    Enrolment
    12,011

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Infant Exposure to Efavirenz
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject

    NCT02159599 · start 2014-07

    Registered record
    Registry ID
    NCT02159599
    Conditions
    HIV Infection
    Interventions
    Darunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2016-04
    Enrolment
    249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionDarunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    PhasePhase 4
    Registry statusCompleted

  • A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

    NCT02263079 · start 2014-06-16

    Registered record
    Registry ID
    NCT02263079
    Conditions
    Pediatric Immuno-Tolerant Chronic Hepatitis B
    Interventions
    Entecavir; Lamivudine; Pegylated Interferon Alfa-2A
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-06-16
    Completion
    2020-01-29
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Immuno-Tolerant Chronic Hepatitis B
    InterventionEntecavir; Lamivudine; Pegylated Interferon Alfa-2A
    PhasePhase 3
    Registry statusCompleted

  • Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir

    NCT02104700 · start 2014-04

    Registered record
    Registry ID
    NCT02104700
    Conditions
    HIV
    Interventions
    Rilpivirine/Emtricitabine/Tenofovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-07
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionRilpivirine/Emtricitabine/Tenofovir
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

    NCT01943799 · start 2013-09-13

    Registered record
    Registry ID
    NCT01943799
    Conditions
    Chronic HBV Infection
    Interventions
    GS-4774; OAV Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09-13
    Completion
    2015-03-03
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic HBV Infection
    InterventionGS-4774; OAV Regimen
    PhasePhase 2
    Registry statusCompleted

  • Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

    NCT01694017 · start 2012-11

    Registered record
    Registry ID
    NCT01694017
    Conditions
    HIV
    Interventions
    Tenofovir; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-08
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTenofovir; Zidovudine
    PhasePhase 4
    Registry statusCompleted

  • Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis

    NCT01693679 · start 2012-09

    Registered record
    Registry ID
    NCT01693679
    Conditions
    HBV-related Liver Cirrhosis
    Interventions
    Telbivudine, Lamivudine, Adefovir ,Enecavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-09
    Completion
    Not recorded
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHBV-related Liver Cirrhosis
    InterventionTelbivudine, Lamivudine, Adefovir ,Enecavir
    PhasePhase 4
    Registry statusUnknown

  • Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression

    NCT01471821 · start 2011-10

    Registered record
    Registry ID
    NCT01471821
    Conditions
    HIV Infection
    Interventions
    antiretroviral treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-10
    Completion
    2014-04
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    Interventionantiretroviral treatment
    PhasePhase 4
    Registry statusCompleted

  • Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

    NCT01366547 · start 2011-06

    Registered record
    Registry ID
    NCT01366547
    Conditions
    Healthy Subjects; Infection, Human Immunodeficiency Virus
    Interventions
    Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg; Dolutegravir 50 mg; abacavir 600 mg/lamivudine 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-06
    Completion
    2011-07
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects; Infection, Human Immunodeficiency Virus
    InterventionDolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg; Dolutegravir 50 mg; abacavir 600 mg/lamivudine 300 mg
    PhasePhase 1
    Registry statusCompleted

  • Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries

    NCT01061151 · start 2011-03-01

    Registered record
    Registry ID
    NCT01061151
    Conditions
    HIV Infections
    Interventions
    Zidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers; Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail; Lamivudine-Zidovudine (3TC-ZDV); Lopinavir-ritonavir (LPV-RTV); Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]); Nevirapine (NVP): Infant short-course; Nevirapine (NVP): Infant extended; No Intervention; Discontinue triple ARVs; Continue triple ARVs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03-01
    Completion
    2016-09-30
    Enrolment
    3,747

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers; Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail; Lamivudine-Zidovudine (3TC-ZDV) +7 more
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

    NCT00799864 · start 2011-01

    Registered record
    Registry ID
    NCT00799864
    Conditions
    HIV-1
    Interventions
    Rilpivirine; Zidovudine; Abacavir; Tenofovir disoproxil fumarate; Lamivudine; Emtricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-01
    Completion
    2022-08
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionRilpivirine; Zidovudine; Abacavir; Tenofovir disoproxil fumarate +2 more
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients

    NCT00943540 · start 2009-07

    Registered record
    Registry ID
    NCT00943540
    Conditions
    HIV Infection; HIV Infections
    Interventions
    raltegravir QD; atazanavir; lamivudine (or emtricitabine)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07
    Completion
    2011-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; HIV Infections
    Interventionraltegravir QD; atazanavir; lamivudine (or emtricitabine)
    PhasePhase 2
    Registry statusCompleted